Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PHGE | S-1 | bearish | 5/10 | BiomX Inc. filed an S-1 registration statement to register 7,163,000 shares of common stock for resale by selling stockh | Jun 29, 2026 |
| HELP | 6-K | mixed | 6/10 | Cybin Inc. (HELP) reported fiscal year 2026 financial results showing a net loss of $148.0 million, nearly double the pr | Jun 29, 2026 |
| NVCT | 424B5 | bearish | 6/10 | Nuvectis Pharma filed a preliminary prospectus supplement for an underwritten public offering of common stock. The offer | Jun 29, 2026 |
| TOMZ | 8-K | bearish | 7/10 | TOMZ signs definitive merger agreement to acquire Carbonium Core, a private nuclear-grade graphite developer, via revers | Jun 29, 2026 |
| XTLB | 6-K | mixed | 6/10 | XTL Biopharmaceuticals held its Extraordinary General Meeting on June 29, 2026, and all proposals were approved. Proposa | Jun 29, 2026 |
| ELTP | 8-K | bullish | 7/10 | Elite Pharmaceuticals reported fiscal year 2026 revenue of $148.9M, up 77% YoY, and operating income of $49.1M, up 151% | Jun 29, 2026 |
| MEOH | 6-K | bearish | 6/10 | Methanex announced it will indefinitely idle its Titan methanol plant (860,000 tonnes/year) in Trinidad after failing to | Jun 29, 2026 |
| TARA | 8-K | neutral | 2/10 | Protara Therapeutics disclosed the resignation of Chief Medical Officer Leonardo Viana Nicacio, M.D., effective June 26, | Jun 29, 2026 |
| SCLX | 8-K | bearish | 7/10 | Scilex Holding Co. entered a binding term sheet to purchase 837 Bitcoin from Datavault AI Inc. for $50 million, payable | Jun 29, 2026 |
| TENX | 8-K | neutral | 3/10 | Tenax Therapeutics amended employment agreements for its CEO, CFO, and CMO to align severance benefits with newly adopte | Jun 29, 2026 |
| PRAX | 8-K | bearish | 6/10 | Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its relutrigine NDA (SC | Jun 29, 2026 |
| UTHR | 8-K | neutral | 2/10 | United Therapeutics shareholders approved the 2026 Stock Incentive Plan at the annual meeting, adding 1,500,000 new shar | Jun 29, 2026 |
| FBLG | 8-K | bearish | 7/10 | FibroBiologics has entered into a securities purchase agreement for a PIPE financing of an undisclosed amount, issuing s | Jun 29, 2026 |
| SDGR | 8-K | bullish | 6/10 | Schrodinger received an approximately $57 million cash payment from Eli Lilly's acquisition of Ajax Therapeutics, a comp | Jun 29, 2026 |
| ARTV | INSIDER-BUY | bullish | 4/10 | RA Capital Management, a 10% owner and director at Artiva Biotherapeutics, purchased ~32.9K shares for $292K over two da | Jun 29, 2026 |
| GANX | PRESS-RELEASE | bullish | 5/10 | Gain Therapeutics announced FDA authorization of its IND application for GT-02287, allowing Phase 2 clinical development | Jun 29, 2026 |
| ABVX | PRESS-RELEASE | bullish | 7/10 | Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, | Jun 29, 2026 |
| TRIB | 6-K | mixed | 5/10 | Trinity Biotech terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, an equity line of credi | Jun 29, 2026 |
| VIR | 144 | neutral | 2/10 | Former director Saira Ramasastry filed a Form 144 on June 29, 2026, indicating intent to sell 16,000 shares of Vir Biote | Jun 29, 2026 |
| ELAN | COURT-RULING | neutral | 2/10 | The Seventh Circuit affirmed summary judgment for Elanco in a class action alleging violations of the Indiana Wage Payme | Jun 29, 2026 |
| GRML | 8-K | neutral | 3/10 | Greenland Mines Ltd. filed an 8-K disclosing a change in independent auditor: BCRG Group was dismissed and Simon & Edwar | Jun 29, 2026 |
| EBS | 8-K | bullish | 5/10 | Emergent BioSolutions received a $52.7 million contract modification from the U.S. government (ASPR) for ACAM2000 vaccin | Jun 29, 2026 |
| CTTH | S-1/A | bearish | 6/10 | CTT Pharmaceutical Holdings filed Amendment No. 4 to its S-1 registration statement, registering 6,250,000 shares for re | Jun 29, 2026 |
| GSK | 6-K | neutral | 3/10 | GSK completed its £2 billion share buyback program, purchasing 123,939,156 ordinary shares since February 24, 2025. The | Jun 29, 2026 |
| GSK | 6-K | neutral | 3/10 | Dodge & Cox, a top-3 institutional holder of GSK, disclosed a reduction in its voting rights stake from 5.01% to 4.96%, | Jun 29, 2026 |
| FDMT | 8-K | bullish | 6/10 | 4D Molecular Therapeutics entered into a $200M senior secured term loan facility with Hercules Capital, drawing an initi | Jun 29, 2026 |
| NRSN | 6-K | bullish | 8/10 | NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in ALS met its primary endpoint with a stat | Jun 29, 2026 |
| TBPH | 8-K | bullish | 7/10 | Theravance Biopharma (TBPH) entered into a definitive merger agreement to be acquired by Zymeworks Inc. for $17.00 per s | Jun 29, 2026 |
| MLYS | 144 | neutral | 3/10 | Eric Warren, an officer of Mineralys Therapeutics, filed a Form 144 notice of intent to sell 104,124 shares of common st | Jun 29, 2026 |
| EVMN | 8-K | bearish | 7/10 | Evommune announced top-line results from its Phase 2b trial of EVO756 in chronic spontaneous urticaria (CSU). The 160-pa | Jun 29, 2026 |